Sign in

NCT05804578Recruiting

Using a Blood Test to Monitor Metastatic Breast Cancer Treatment

Using a Liquid Biopsy to Monitor Metastatic Breast Cancer Treatment

Source: ClinicalTrials.gov · Last updated 25 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.

Status (registry)
Recruiting
Study type
Observational
Enrollment
150 (estimated)
First submitted
27 Mar 2023
Start date
19 Oct 2023
Primary completion date
Jan 2026
Lead sponsor
Dr. Christopher Mueller
NCT number
NCT05804578

What you commit to

  • Study type: Observational
  • Planned participants: 150
  • From 19 Oct 2023 to the primary completion date, Jan 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • -Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]

Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario
Coordinator of this site? Confirm its status
KingstonCanadaRecruiting
Sunnybrook Health Sciences Centre
Coordinator of this site? Confirm its status
TorontoCanadaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.